2020 Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Post-Traumatic Stress Disorder (PTSD) pipeline report presents a comprehensive overview of the research and development of Post-Traumatic Stress Disorder (PTSD) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Five drugs in Research phase, 20 drugs in pre-clinical phase, two drugs in Phase 1, five drugs in Phase 2, and three drugs in Phase 3
As of February 2020, the Post-Traumatic Stress Disorder (PTSD) pipeline remains robust with 36 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Post-Traumatic Stress Disorder (PTSD) treatment. Diverse types of targeted therapies are being explored through clinical trials including 11 beta-HSD1 inhibitor; Adrenergic receptor agonists; Alpha 1 adrenergic receptor antagonist; alpha 7 nicotinic acetylcholine receptor antagonist; AMPA receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists; Cannabinoid receptor modulators; Dopamine D2 receptor partial agonists; DYRK kinase inhibitor; enzyme acetyl-CoA synthetase 2 (ACSS2) inhibitor; fatty acid amide hydrolase (FAAH) inhibitor; GABA A receptor agonists; GABA aminotransferase inhibitor; Glucocorticoid receptor antagonist; glucocorticoid receptor II antagonists; glutamate receptor inhibitor; HDAC3 protein inhibitors; Histamine H1 receptor antagonist; Metabotropic glutamate receptor 2 modulator (mGluR2); metabotropic glutamate receptor 7 (mGlu7) antagonists; NMDA receptor antagonists; Protein phosphatase 2A inhibitor; PSD-95/nNOS inhibitors; Ryanodine Receptor (RyR); serotonin 5-HT2A receptor antagonists; Serotonin uptake stimulants; Tropomyosin Receptor Kinase B (TrKB); vasopressin 1a receptor antagonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Post-Traumatic Stress Disorder (PTSD) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Post-Traumatic Stress Disorder (PTSD) pipeline drugs profiled in the report include- Xanamem (UE-2343),ADX71743,mGluR7 antagonist,Small Molecules for Depression and Post-Traumatic Stress Disorder,AC002,Small Molecules to Target NMDA Receptor,ZL006,NYX-783,Rycal,ART27.13,SRX246,BNC210,CBIS-PTSD-001,CPP-115,CDTP-003,Glucocorticoid Receptor II for Post Traumatic Stress Disorder,IC87201,EMB-001 (metyrapone/oxazepam),small molecule inhibitor of ACSS2,IMM-201,Small molecule for cognition disorders,ADX 71149 (JNJ-40411813),KDAC0001,LB-100,midomafetamine,NNI-351,NMDA receptor for PTSD,glutamatergic AMPA receptor for Post-Traumatic Stress Disorder,NBTX-001,brexpiprazole,QRX002,SAR-411298,ketamine hydrochloride,TNX-102,TNX-601 (tianeptine oxalate),TNX-1600
As of February 2020, the Post-Traumatic Stress Disorder (PTSD) pipeline remains robust with 36 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Post-Traumatic Stress Disorder (PTSD) treatment. Diverse types of targeted therapies are being explored through clinical trials including 11 beta-HSD1 inhibitor; Adrenergic receptor agonists; Alpha 1 adrenergic receptor antagonist; alpha 7 nicotinic acetylcholine receptor antagonist; AMPA receptor agonists; Cannabinoid receptor CB1 agonists; Cannabinoid receptor CB2 agonists; Cannabinoid receptor modulators; Dopamine D2 receptor partial agonists; DYRK kinase inhibitor; enzyme acetyl-CoA synthetase 2 (ACSS2) inhibitor; fatty acid amide hydrolase (FAAH) inhibitor; GABA A receptor agonists; GABA aminotransferase inhibitor; Glucocorticoid receptor antagonist; glucocorticoid receptor II antagonists; glutamate receptor inhibitor; HDAC3 protein inhibitors; Histamine H1 receptor antagonist; Metabotropic glutamate receptor 2 modulator (mGluR2); metabotropic glutamate receptor 7 (mGlu7) antagonists; NMDA receptor antagonists; Protein phosphatase 2A inhibitor; PSD-95/nNOS inhibitors; Ryanodine Receptor (RyR); serotonin 5-HT2A receptor antagonists; Serotonin uptake stimulants; Tropomyosin Receptor Kinase B (TrKB); vasopressin 1a receptor antagonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Post-Traumatic Stress Disorder (PTSD) drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Post-Traumatic Stress Disorder (PTSD) development
- Post-Traumatic Stress Disorder (PTSD) pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Post-Traumatic Stress Disorder (PTSD) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Post-Traumatic Stress Disorder (PTSD) pipeline candidates included
- Business overview and snapshot of all companies involved in Post-Traumatic Stress Disorder (PTSD) pipeline are included
- Latest market and pipeline developments are provided in the report
Post-Traumatic Stress Disorder (PTSD) pipeline drugs profiled in the report include- Xanamem (UE-2343),ADX71743,mGluR7 antagonist,Small Molecules for Depression and Post-Traumatic Stress Disorder,AC002,Small Molecules to Target NMDA Receptor,ZL006,NYX-783,Rycal,ART27.13,SRX246,BNC210,CBIS-PTSD-001,CPP-115,CDTP-003,Glucocorticoid Receptor II for Post Traumatic Stress Disorder,IC87201,EMB-001 (metyrapone/oxazepam),small molecule inhibitor of ACSS2,IMM-201,Small molecule for cognition disorders,ADX 71149 (JNJ-40411813),KDAC0001,LB-100,midomafetamine,NNI-351,NMDA receptor for PTSD,glutamatergic AMPA receptor for Post-Traumatic Stress Disorder,NBTX-001,brexpiprazole,QRX002,SAR-411298,ketamine hydrochloride,TNX-102,TNX-601 (tianeptine oxalate),TNX-1600
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Post-Traumatic Stress Disorder (PTSD) Condition
2.3 Post-Traumatic Stress Disorder (PTSD) Pipeline Snapshot, 2020
2.4 Companies investing in Post-Traumatic Stress Disorder (PTSD) pipeline therapeutics
2.5 Phase wise Post-Traumatic Stress Disorder (PTSD) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Post-Traumatic Stress Disorder (PTSD) Pipeline Products
2.7 Route of Administration of Post-Traumatic Stress Disorder (PTSD) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Actinogen Medical Ltd Overview, Contacts and ASD Pipeline Drugs
3.2 Addex Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Aision Biotechnologies Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Allied Corp Overview, Contacts and ASD Pipeline Drugs
3.5 Amorsa Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Anagin Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Aptinyx Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Armgo Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Artelo Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.10 Azevan Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.11 Bionomics Ltd Overview, Contacts and ASD Pipeline Drugs
3.12 Cannabis Science Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Catalyst Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.14 Chronos Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.15 Corcept Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.16 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.17 Embera NeuroTherapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.18 EpiVario Inc Overview, Contacts and ASD Pipeline Drugs
3.19 Immodulon Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.20 INVENT Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.21 Kdac Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.22 Lixte Biotechnology Holdings Inc Overview, Contacts and ASD Pipeline Drugs
3.23 MAPS Euroape B.V. Overview, Contacts and ASD Pipeline Drugs
3.24 NeuroNascent Inc Overview, Contacts and ASD Pipeline Drugs
3.25 NeuroRx Inc Overview, Contacts and ASD Pipeline Drugs
3.26 Neurovation Labs Inc Overview, Contacts and ASD Pipeline Drugs
3.27 Nobilis Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.28 Otsuka Holdings Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.29 Quoin Pharmaceuticals Ltd Overview, Contacts and ASD Pipeline Drugs
3.30 Sanofi Overview, Contacts and ASD Pipeline Drugs
3.31 Seelos Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.32 Tonix Pharmaceuticals Holding Corp Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 Xanamem (UE-2343) Drug Details
4.1.1 Xanamem (UE-2343) Current Status
4.1.2 Xanamem (UE-2343) Drug Overview
4.1.3 Xanamem (UE-2343) Mechanism of Action
4.1.4 Xanamem (UE-2343) Licensing/Collaboration Companies
4.1.5 Xanamem (UE-2343) Clinical Trials
4.2 ADX71743 Drug Details
4.2.1 ADX71743 Current Status
4.2.2 ADX71743 Drug Overview
4.2.3 ADX71743 Mechanism of Action
4.2.4 ADX71743 Licensing/Collaboration Companies
4.2.5 ADX71743 Clinical Trials
4.3 mGluR7 antagonist Drug Details
4.3.1 mGluR7 antagonist Current Status
4.3.2 mGluR7 antagonist Drug Overview
4.3.3 mGluR7 antagonist Mechanism of Action
4.3.4 mGluR7 antagonist Licensing/Collaboration Companies
4.3.5 mGluR7 antagonist Clinical Trials
4.4 Small Molecules for Depression and Post-Traumatic Stress Disorder Drug Details
4.4.1 Small Molecules for Depression and Post-Traumatic Stress Disorder Current Status
4.4.2 Small Molecules for Depression and Post-Traumatic Stress Disorder Drug Overview
4.4.3 Small Molecules for Depression and Post-Traumatic Stress Disorder Mechanism of Action
4.4.4 Small Molecules for Depression and Post-Traumatic Stress Disorder Licensing/Collaboration Companies
4.4.5 Small Molecules for Depression and Post-Traumatic Stress Disorder Clinical Trials
4.5 AC002 Drug Details
4.5.1 AC002 Current Status
4.5.2 AC002 Drug Overview
4.5.3 AC002 Mechanism of Action
4.5.4 AC002 Licensing/Collaboration Companies
4.5.5 AC002 Clinical Trials
4.6 Small Molecules to Target NMDA Receptor Drug Details
4.6.1 Small Molecules to Target NMDA Receptor Current Status
4.6.2 Small Molecules to Target NMDA Receptor Drug Overview
4.6.3 Small Molecules to Target NMDA Receptor Mechanism of Action
4.6.4 Small Molecules to Target NMDA Receptor Licensing/Collaboration Companies
4.6.5 Small Molecules to Target NMDA Receptor Clinical Trials
4.7 ZL006 Drug Details
4.7.1 ZL006 Current Status
4.7.2 ZL006 Drug Overview
4.7.3 ZL006 Mechanism of Action
4.7.4 ZL006 Licensing/Collaboration Companies
4.7.5 ZL006 Clinical Trials
4.8 NYX-783 Drug Details
4.8.1 NYX-783 Current Status
4.8.2 NYX-783 Drug Overview
4.8.3 NYX-783 Mechanism of Action
4.8.4 NYX-783 Licensing/Collaboration Companies
4.8.5 NYX-783 Clinical Trials
4.9 Rycal Drug Details
4.9.1 Rycal Current Status
4.9.2 Rycal Drug Overview
4.9.3 Rycal Mechanism of Action
4.9.4 Rycal Licensing/Collaboration Companies
4.9.5 Rycal Clinical Trials
4.10 ART27.13 Drug Details
4.10.1 ART27.13 Current Status
4.10.2 ART27.13 Drug Overview
4.10.3 ART27.13 Mechanism of Action
4.10.4 ART27.13 Licensing/Collaboration Companies
4.10.5 ART27.13 Clinical Trials
4.11 SRX246 Drug Details
4.11.1 SRX246 Current Status
4.11.2 SRX246 Drug Overview
4.11.3 SRX246 Mechanism of Action
4.11.4 SRX246 Licensing/Collaboration Companies
4.11.5 SRX246 Clinical Trials
4.12 BNC210 Drug Details
4.12.1 BNC210 Current Status
4.12.2 BNC210 Drug Overview
4.12.3 BNC210 Mechanism of Action
4.12.4 BNC210 Licensing/Collaboration Companies
4.12.5 BNC210 Clinical Trials
4.13 CBIS-PTSD-001 Drug Details
4.13.1 CBIS-PTSD-001 Current Status
4.13.2 CBIS-PTSD-001 Drug Overview
4.13.3 CBIS-PTSD-001 Mechanism of Action
4.13.4 CBIS-PTSD-001 Licensing/Collaboration Companies
4.13.5 CBIS-PTSD-001 Clinical Trials
4.14 CPP-115 Drug Details
4.14.1 CPP-115 Current Status
4.14.2 CPP-115 Drug Overview
4.14.3 CPP-115 Mechanism of Action
4.14.4 CPP-115 Licensing/Collaboration Companies
4.14.5 CPP-115 Clinical Trials
4.15 CDTP-003 Drug Details
4.15.1 CDTP-003 Current Status
4.15.2 CDTP-003 Drug Overview
4.15.3 CDTP-003 Mechanism of Action
4.15.4 CDTP-003 Licensing/Collaboration Companies
4.15.5 CDTP-003 Clinical Trials
4.16 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Drug Details
4.16.1 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Current Status
4.16.2 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Drug Overview
4.16.3 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Mechanism of Action
4.16.4 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Licensing/Collaboration Companies
4.16.5 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Clinical Trials
4.17 IC87201 Drug Details
4.17.1 IC87201 Current Status
4.17.2 IC87201 Drug Overview
4.17.3 IC87201 Mechanism of Action
4.17.4 IC87201 Licensing/Collaboration Companies
4.17.5 IC87201 Clinical Trials
4.18 EMB-001 (metyrapone/oxazepam) Drug Details
4.18.1 EMB-001 (metyrapone/oxazepam) Current Status
4.18.2 EMB-001 (metyrapone/oxazepam) Drug Overview
4.18.3 EMB-001 (metyrapone/oxazepam) Mechanism of Action
4.18.4 EMB-001 (metyrapone/oxazepam) Licensing/Collaboration Companies
4.18.5 EMB-001 (metyrapone/oxazepam) Clinical Trials
4.19 small molecule inhibitor of ACSS2 Drug Details
4.19.1 small molecule inhibitor of ACSS2 Current Status
4.19.2 small molecule inhibitor of ACSS2 Drug Overview
4.19.3 small molecule inhibitor of ACSS2 Mechanism of Action
4.19.4 small molecule inhibitor of ACSS2 Licensing/Collaboration Companies
4.19.5 small molecule inhibitor of ACSS2 Clinical Trials
4.20 IMM-201 Drug Details
4.20.1 IMM-201 Current Status
4.20.2 IMM-201 Drug Overview
4.20.3 IMM-201 Mechanism of Action
4.20.4 IMM-201 Licensing/Collaboration Companies
4.20.5 IMM-201 Clinical Trials
4.21 Small molecule for cognition disorders Drug Details
4.21.1 Small molecule for cognition disorders Current Status
4.21.2 Small molecule for cognition disorders Drug Overview
4.21.3 Small molecule for cognition disorders Mechanism of Action
4.21.4 Small molecule for cognition disorders Licensing/Collaboration Companies
4.21.5 Small molecule for cognition disorders Clinical Trials
4.22 ADX 71149 (JNJ-40411813) Drug Details
4.22.1 ADX 71149 (JNJ-40411813) Current Status
4.22.2 ADX 71149 (JNJ-40411813) Drug Overview
4.22.3 ADX 71149 (JNJ-40411813) Mechanism of Action
4.22.4 ADX 71149 (JNJ-40411813) Licensing/Collaboration Companies
4.22.5 ADX 71149 (JNJ-40411813) Clinical Trials
4.23 KDAC0001 Drug Details
4.23.1 KDAC0001 Current Status
4.23.2 KDAC0001 Drug Overview
4.23.3 KDAC0001 Mechanism of Action
4.23.4 KDAC0001 Licensing/Collaboration Companies
4.23.5 KDAC0001 Clinical Trials
4.24 LB-100 Drug Details
4.24.1 LB-100 Current Status
4.24.2 LB-100 Drug Overview
4.24.3 LB-100 Mechanism of Action
4.24.4 LB-100 Licensing/Collaboration Companies
4.24.5 LB-100 Clinical Trials
4.25 midomafetamine Drug Details
4.25.1 midomafetamine Current Status
4.25.2 midomafetamine Drug Overview
4.25.3 midomafetamine Mechanism of Action
4.25.4 midomafetamine Licensing/Collaboration Companies
4.25.5 midomafetamine Clinical Trials
4.26 NNI-351 Drug Details
4.26.1 NNI-351 Current Status
4.26.2 NNI-351 Drug Overview
4.26.3 NNI-351 Mechanism of Action
4.26.4 NNI-351 Licensing/Collaboration Companies
4.26.5 NNI-351 Clinical Trials
4.27 NMDA receptor for PTSD Drug Details
4.27.1 NMDA receptor for PTSD Current Status
4.27.2 NMDA receptor for PTSD Drug Overview
4.27.3 NMDA receptor for PTSD Mechanism of Action
4.27.4 NMDA receptor for PTSD Licensing/Collaboration Companies
4.27.5 NMDA receptor for PTSD Clinical Trials
4.28 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Drug Details
4.28.1 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Current Status
4.28.2 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Drug Overview
4.28.3 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Mechanism of Action
4.28.4 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Licensing/Collaboration Companies
4.28.5 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Clinical Trials
4.29 NBTX-001 Drug Details
4.29.1 NBTX-001 Current Status
4.29.2 NBTX-001 Drug Overview
4.29.3 NBTX-001 Mechanism of Action
4.29.4 NBTX-001 Licensing/Collaboration Companies
4.29.5 NBTX-001 Clinical Trials
4.30 brexpiprazole Drug Details
4.30.1 brexpiprazole Current Status
4.30.2 brexpiprazole Drug Overview
4.30.3 brexpiprazole Mechanism of Action
4.30.4 brexpiprazole Licensing/Collaboration Companies
4.30.5 brexpiprazole Clinical Trials
4.31 QRX002 Drug Details
4.31.1 QRX002 Current Status
4.31.2 QRX002 Drug Overview
4.31.3 QRX002 Mechanism of Action
4.31.4 QRX002 Licensing/Collaboration Companies
4.31.5 QRX002 Clinical Trials
4.32 SAR-411298 Drug Details
4.32.1 SAR-411298 Current Status
4.32.2 SAR-411298 Drug Overview
4.32.3 SAR-411298 Mechanism of Action
4.32.4 SAR-411298 Licensing/Collaboration Companies
4.32.5 SAR-411298 Clinical Trials
4.33 ketamine hydrochloride Drug Details
4.33.1 ketamine hydrochloride Current Status
4.33.2 ketamine hydrochloride Drug Overview
4.33.3 ketamine hydrochloride Mechanism of Action
4.33.4 ketamine hydrochloride Licensing/Collaboration Companies
4.33.5 ketamine hydrochloride Clinical Trials
4.34 TNX-102 Drug Details
4.34.1 TNX-102 Current Status
4.34.2 TNX-102 Drug Overview
4.34.3 TNX-102 Mechanism of Action
4.34.4 TNX-102 Licensing/Collaboration Companies
4.34.5 TNX-102 Clinical Trials
4.35 TNX-601 (tianeptine oxalate) Drug Details
4.35.1 TNX-601 (tianeptine oxalate) Current Status
4.35.2 TNX-601 (tianeptine oxalate) Drug Overview
4.35.3 TNX-601 (tianeptine oxalate) Mechanism of Action
4.35.4 TNX-601 (tianeptine oxalate) Licensing/Collaboration Companies
4.35.5 TNX-601 (tianeptine oxalate) Clinical Trials
4.36 TNX-1600 Drug Details
4.36.1 TNX-1600 Current Status
4.36.2 TNX-1600 Drug Overview
4.36.3 TNX-1600 Mechanism of Action
4.36.4 TNX-1600 Licensing/Collaboration Companies
4.36.5 TNX-1600 Clinical Trials
5. LATEST POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Post-Traumatic Stress Disorder (PTSD) Condition
2.3 Post-Traumatic Stress Disorder (PTSD) Pipeline Snapshot, 2020
2.4 Companies investing in Post-Traumatic Stress Disorder (PTSD) pipeline therapeutics
2.5 Phase wise Post-Traumatic Stress Disorder (PTSD) Pipeline Candidates
2.6 Most Researched Mechanism of Action of Post-Traumatic Stress Disorder (PTSD) Pipeline Products
2.7 Route of Administration of Post-Traumatic Stress Disorder (PTSD) Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Actinogen Medical Ltd Overview, Contacts and ASD Pipeline Drugs
3.2 Addex Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.3 Aision Biotechnologies Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Allied Corp Overview, Contacts and ASD Pipeline Drugs
3.5 Amorsa Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.6 Anagin Inc Overview, Contacts and ASD Pipeline Drugs
3.7 Aptinyx Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Armgo Pharma Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Artelo Biosciences Inc Overview, Contacts and ASD Pipeline Drugs
3.10 Azevan Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.11 Bionomics Ltd Overview, Contacts and ASD Pipeline Drugs
3.12 Cannabis Science Inc Overview, Contacts and ASD Pipeline Drugs
3.13 Catalyst Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.14 Chronos Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.15 Corcept Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.16 Eli Lilly and Co Overview, Contacts and ASD Pipeline Drugs
3.17 Embera NeuroTherapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.18 EpiVario Inc Overview, Contacts and ASD Pipeline Drugs
3.19 Immodulon Therapeutics Ltd Overview, Contacts and ASD Pipeline Drugs
3.20 INVENT Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
3.21 Kdac Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.22 Lixte Biotechnology Holdings Inc Overview, Contacts and ASD Pipeline Drugs
3.23 MAPS Euroape B.V. Overview, Contacts and ASD Pipeline Drugs
3.24 NeuroNascent Inc Overview, Contacts and ASD Pipeline Drugs
3.25 NeuroRx Inc Overview, Contacts and ASD Pipeline Drugs
3.26 Neurovation Labs Inc Overview, Contacts and ASD Pipeline Drugs
3.27 Nobilis Therapeutics Overview, Contacts and ASD Pipeline Drugs
3.28 Otsuka Holdings Co Ltd Overview, Contacts and ASD Pipeline Drugs
3.29 Quoin Pharmaceuticals Ltd Overview, Contacts and ASD Pipeline Drugs
3.30 Sanofi Overview, Contacts and ASD Pipeline Drugs
3.31 Seelos Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.32 Tonix Pharmaceuticals Holding Corp Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 Xanamem (UE-2343) Drug Details
4.1.1 Xanamem (UE-2343) Current Status
4.1.2 Xanamem (UE-2343) Drug Overview
4.1.3 Xanamem (UE-2343) Mechanism of Action
4.1.4 Xanamem (UE-2343) Licensing/Collaboration Companies
4.1.5 Xanamem (UE-2343) Clinical Trials
4.2 ADX71743 Drug Details
4.2.1 ADX71743 Current Status
4.2.2 ADX71743 Drug Overview
4.2.3 ADX71743 Mechanism of Action
4.2.4 ADX71743 Licensing/Collaboration Companies
4.2.5 ADX71743 Clinical Trials
4.3 mGluR7 antagonist Drug Details
4.3.1 mGluR7 antagonist Current Status
4.3.2 mGluR7 antagonist Drug Overview
4.3.3 mGluR7 antagonist Mechanism of Action
4.3.4 mGluR7 antagonist Licensing/Collaboration Companies
4.3.5 mGluR7 antagonist Clinical Trials
4.4 Small Molecules for Depression and Post-Traumatic Stress Disorder Drug Details
4.4.1 Small Molecules for Depression and Post-Traumatic Stress Disorder Current Status
4.4.2 Small Molecules for Depression and Post-Traumatic Stress Disorder Drug Overview
4.4.3 Small Molecules for Depression and Post-Traumatic Stress Disorder Mechanism of Action
4.4.4 Small Molecules for Depression and Post-Traumatic Stress Disorder Licensing/Collaboration Companies
4.4.5 Small Molecules for Depression and Post-Traumatic Stress Disorder Clinical Trials
4.5 AC002 Drug Details
4.5.1 AC002 Current Status
4.5.2 AC002 Drug Overview
4.5.3 AC002 Mechanism of Action
4.5.4 AC002 Licensing/Collaboration Companies
4.5.5 AC002 Clinical Trials
4.6 Small Molecules to Target NMDA Receptor Drug Details
4.6.1 Small Molecules to Target NMDA Receptor Current Status
4.6.2 Small Molecules to Target NMDA Receptor Drug Overview
4.6.3 Small Molecules to Target NMDA Receptor Mechanism of Action
4.6.4 Small Molecules to Target NMDA Receptor Licensing/Collaboration Companies
4.6.5 Small Molecules to Target NMDA Receptor Clinical Trials
4.7 ZL006 Drug Details
4.7.1 ZL006 Current Status
4.7.2 ZL006 Drug Overview
4.7.3 ZL006 Mechanism of Action
4.7.4 ZL006 Licensing/Collaboration Companies
4.7.5 ZL006 Clinical Trials
4.8 NYX-783 Drug Details
4.8.1 NYX-783 Current Status
4.8.2 NYX-783 Drug Overview
4.8.3 NYX-783 Mechanism of Action
4.8.4 NYX-783 Licensing/Collaboration Companies
4.8.5 NYX-783 Clinical Trials
4.9 Rycal Drug Details
4.9.1 Rycal Current Status
4.9.2 Rycal Drug Overview
4.9.3 Rycal Mechanism of Action
4.9.4 Rycal Licensing/Collaboration Companies
4.9.5 Rycal Clinical Trials
4.10 ART27.13 Drug Details
4.10.1 ART27.13 Current Status
4.10.2 ART27.13 Drug Overview
4.10.3 ART27.13 Mechanism of Action
4.10.4 ART27.13 Licensing/Collaboration Companies
4.10.5 ART27.13 Clinical Trials
4.11 SRX246 Drug Details
4.11.1 SRX246 Current Status
4.11.2 SRX246 Drug Overview
4.11.3 SRX246 Mechanism of Action
4.11.4 SRX246 Licensing/Collaboration Companies
4.11.5 SRX246 Clinical Trials
4.12 BNC210 Drug Details
4.12.1 BNC210 Current Status
4.12.2 BNC210 Drug Overview
4.12.3 BNC210 Mechanism of Action
4.12.4 BNC210 Licensing/Collaboration Companies
4.12.5 BNC210 Clinical Trials
4.13 CBIS-PTSD-001 Drug Details
4.13.1 CBIS-PTSD-001 Current Status
4.13.2 CBIS-PTSD-001 Drug Overview
4.13.3 CBIS-PTSD-001 Mechanism of Action
4.13.4 CBIS-PTSD-001 Licensing/Collaboration Companies
4.13.5 CBIS-PTSD-001 Clinical Trials
4.14 CPP-115 Drug Details
4.14.1 CPP-115 Current Status
4.14.2 CPP-115 Drug Overview
4.14.3 CPP-115 Mechanism of Action
4.14.4 CPP-115 Licensing/Collaboration Companies
4.14.5 CPP-115 Clinical Trials
4.15 CDTP-003 Drug Details
4.15.1 CDTP-003 Current Status
4.15.2 CDTP-003 Drug Overview
4.15.3 CDTP-003 Mechanism of Action
4.15.4 CDTP-003 Licensing/Collaboration Companies
4.15.5 CDTP-003 Clinical Trials
4.16 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Drug Details
4.16.1 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Current Status
4.16.2 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Drug Overview
4.16.3 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Mechanism of Action
4.16.4 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Licensing/Collaboration Companies
4.16.5 Glucocorticoid Receptor II for Post Traumatic Stress Disorder Clinical Trials
4.17 IC87201 Drug Details
4.17.1 IC87201 Current Status
4.17.2 IC87201 Drug Overview
4.17.3 IC87201 Mechanism of Action
4.17.4 IC87201 Licensing/Collaboration Companies
4.17.5 IC87201 Clinical Trials
4.18 EMB-001 (metyrapone/oxazepam) Drug Details
4.18.1 EMB-001 (metyrapone/oxazepam) Current Status
4.18.2 EMB-001 (metyrapone/oxazepam) Drug Overview
4.18.3 EMB-001 (metyrapone/oxazepam) Mechanism of Action
4.18.4 EMB-001 (metyrapone/oxazepam) Licensing/Collaboration Companies
4.18.5 EMB-001 (metyrapone/oxazepam) Clinical Trials
4.19 small molecule inhibitor of ACSS2 Drug Details
4.19.1 small molecule inhibitor of ACSS2 Current Status
4.19.2 small molecule inhibitor of ACSS2 Drug Overview
4.19.3 small molecule inhibitor of ACSS2 Mechanism of Action
4.19.4 small molecule inhibitor of ACSS2 Licensing/Collaboration Companies
4.19.5 small molecule inhibitor of ACSS2 Clinical Trials
4.20 IMM-201 Drug Details
4.20.1 IMM-201 Current Status
4.20.2 IMM-201 Drug Overview
4.20.3 IMM-201 Mechanism of Action
4.20.4 IMM-201 Licensing/Collaboration Companies
4.20.5 IMM-201 Clinical Trials
4.21 Small molecule for cognition disorders Drug Details
4.21.1 Small molecule for cognition disorders Current Status
4.21.2 Small molecule for cognition disorders Drug Overview
4.21.3 Small molecule for cognition disorders Mechanism of Action
4.21.4 Small molecule for cognition disorders Licensing/Collaboration Companies
4.21.5 Small molecule for cognition disorders Clinical Trials
4.22 ADX 71149 (JNJ-40411813) Drug Details
4.22.1 ADX 71149 (JNJ-40411813) Current Status
4.22.2 ADX 71149 (JNJ-40411813) Drug Overview
4.22.3 ADX 71149 (JNJ-40411813) Mechanism of Action
4.22.4 ADX 71149 (JNJ-40411813) Licensing/Collaboration Companies
4.22.5 ADX 71149 (JNJ-40411813) Clinical Trials
4.23 KDAC0001 Drug Details
4.23.1 KDAC0001 Current Status
4.23.2 KDAC0001 Drug Overview
4.23.3 KDAC0001 Mechanism of Action
4.23.4 KDAC0001 Licensing/Collaboration Companies
4.23.5 KDAC0001 Clinical Trials
4.24 LB-100 Drug Details
4.24.1 LB-100 Current Status
4.24.2 LB-100 Drug Overview
4.24.3 LB-100 Mechanism of Action
4.24.4 LB-100 Licensing/Collaboration Companies
4.24.5 LB-100 Clinical Trials
4.25 midomafetamine Drug Details
4.25.1 midomafetamine Current Status
4.25.2 midomafetamine Drug Overview
4.25.3 midomafetamine Mechanism of Action
4.25.4 midomafetamine Licensing/Collaboration Companies
4.25.5 midomafetamine Clinical Trials
4.26 NNI-351 Drug Details
4.26.1 NNI-351 Current Status
4.26.2 NNI-351 Drug Overview
4.26.3 NNI-351 Mechanism of Action
4.26.4 NNI-351 Licensing/Collaboration Companies
4.26.5 NNI-351 Clinical Trials
4.27 NMDA receptor for PTSD Drug Details
4.27.1 NMDA receptor for PTSD Current Status
4.27.2 NMDA receptor for PTSD Drug Overview
4.27.3 NMDA receptor for PTSD Mechanism of Action
4.27.4 NMDA receptor for PTSD Licensing/Collaboration Companies
4.27.5 NMDA receptor for PTSD Clinical Trials
4.28 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Drug Details
4.28.1 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Current Status
4.28.2 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Drug Overview
4.28.3 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Mechanism of Action
4.28.4 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Licensing/Collaboration Companies
4.28.5 glutamatergic AMPA receptor for Post-Traumatic Stress Disorder Clinical Trials
4.29 NBTX-001 Drug Details
4.29.1 NBTX-001 Current Status
4.29.2 NBTX-001 Drug Overview
4.29.3 NBTX-001 Mechanism of Action
4.29.4 NBTX-001 Licensing/Collaboration Companies
4.29.5 NBTX-001 Clinical Trials
4.30 brexpiprazole Drug Details
4.30.1 brexpiprazole Current Status
4.30.2 brexpiprazole Drug Overview
4.30.3 brexpiprazole Mechanism of Action
4.30.4 brexpiprazole Licensing/Collaboration Companies
4.30.5 brexpiprazole Clinical Trials
4.31 QRX002 Drug Details
4.31.1 QRX002 Current Status
4.31.2 QRX002 Drug Overview
4.31.3 QRX002 Mechanism of Action
4.31.4 QRX002 Licensing/Collaboration Companies
4.31.5 QRX002 Clinical Trials
4.32 SAR-411298 Drug Details
4.32.1 SAR-411298 Current Status
4.32.2 SAR-411298 Drug Overview
4.32.3 SAR-411298 Mechanism of Action
4.32.4 SAR-411298 Licensing/Collaboration Companies
4.32.5 SAR-411298 Clinical Trials
4.33 ketamine hydrochloride Drug Details
4.33.1 ketamine hydrochloride Current Status
4.33.2 ketamine hydrochloride Drug Overview
4.33.3 ketamine hydrochloride Mechanism of Action
4.33.4 ketamine hydrochloride Licensing/Collaboration Companies
4.33.5 ketamine hydrochloride Clinical Trials
4.34 TNX-102 Drug Details
4.34.1 TNX-102 Current Status
4.34.2 TNX-102 Drug Overview
4.34.3 TNX-102 Mechanism of Action
4.34.4 TNX-102 Licensing/Collaboration Companies
4.34.5 TNX-102 Clinical Trials
4.35 TNX-601 (tianeptine oxalate) Drug Details
4.35.1 TNX-601 (tianeptine oxalate) Current Status
4.35.2 TNX-601 (tianeptine oxalate) Drug Overview
4.35.3 TNX-601 (tianeptine oxalate) Mechanism of Action
4.35.4 TNX-601 (tianeptine oxalate) Licensing/Collaboration Companies
4.35.5 TNX-601 (tianeptine oxalate) Clinical Trials
4.36 TNX-1600 Drug Details
4.36.1 TNX-1600 Current Status
4.36.2 TNX-1600 Drug Overview
4.36.3 TNX-1600 Mechanism of Action
4.36.4 TNX-1600 Licensing/Collaboration Companies
4.36.5 TNX-1600 Clinical Trials
5. LATEST POST-TRAUMATIC STRESS DISORDER (PTSD) PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
